# Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

> **NCT03011814** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 38 (actual)

## Conditions studied

- Folliculotropic Mycosis Fungoides
- Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma
- Recurrent Mycosis Fungoides
- Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
- Refractory Mycosis Fungoides
- Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Sezary Syndrome
- Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Durvalumab
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT03011814
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-03-08
- **Primary completion:** 2026-06-23
- **Final completion:** 2026-08-30
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03011814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03011814, "Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03011814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*